Tides 周递 | 全球多肽和寡核苷酸药物一周要闻(10.30-11.7)

多肽圈
Nov 08, 2025

东阳光药自研乙肝小核酸新药国内获批临床2025年10月30日,国家药品监督管理局药品审评中心公开信息显示,东阳光药自主研发的siRNA疗法——HECN30227已获临床试验默示许可,批准开展慢性乙型肝炎(以下简称乙肝)适应症的临床试验。目前全球尚无乙肝siRNA药物获批上市。HECN30227是东阳光药自主研发并拥有全球知识产权的1类新药,也是公司基于小核酸技术平台开发的首款siRNA药物,可同时...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10